Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1999 1
2003 1
2005 2
2008 2
2009 1
2011 1
2012 1
2013 1
2016 2
2018 1
2019 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Bibbins-Domingo K; U.S. Preventive Services Task Force. Bibbins-Domingo K, et al. Ann Intern Med. 2016 Jun 21;164(12):836-45. doi: 10.7326/M16-0577. Epub 2016 Apr 12. Ann Intern Med. 2016. PMID: 27064677 Free article.
DESCRIPTION: Update of the 2009 USPSTF recommendation on aspirin use to prevent cardiovascular disease (CVD) events and the 2007 recommendation on aspirin and nonsteroidal anti-inflammatory drug use to prevent colorectal cancer (CRC). ...(C recommendation) Th …
DESCRIPTION: Update of the 2009 USPSTF recommendation on aspirin use to prevent cardiovascular disease (CVD) events and the 2007 reco …
Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation.
Jia YM, Ge PX, Zhou H, Ji JZ, Tai T, Gu TT, Zhu T, Li YF, Mi QY, Huang BB, Xie HG. Jia YM, et al. Biomed Pharmacother. 2019 Jul;115:108906. doi: 10.1016/j.biopha.2019.108906. Epub 2019 May 3. Biomed Pharmacother. 2019. PMID: 31060007 Free article.
The results showed that concomitant use of vicagrel (5, 10, or 20 mg/kg) led to an average of 55% and 77% increases in systemic exposure of aspirin (C(max) and AUC(0-t)) and 2.8-fold increase in suppression of AA-induced platelet aggregation in mice when compared wi …
The results showed that concomitant use of vicagrel (5, 10, or 20 mg/kg) led to an average of 55% and 77% increases in systemic exposure of …
A rapid method for the simultaneous determination of L-ascorbic acid and acetylsalicylic acid in aspirin C effervescent tablet by ultra performance liquid chromatography-tandem mass spectrometry.
Wabaidur SM, Alothman ZA, Khan MR. Wabaidur SM, et al. Spectrochim Acta A Mol Biomol Spectrosc. 2013 May;108:20-5. doi: 10.1016/j.saa.2013.01.070. Epub 2013 Feb 6. Spectrochim Acta A Mol Biomol Spectrosc. 2013. PMID: 23454710
In present study, a rapid and sensitive method using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed for the simultaneous determination of L-ascorbic acid and acetylsalicylic acid in aspirin C effervescent tablet. The opti …
In present study, a rapid and sensitive method using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was devel …
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Chen J, Bhatt DL, Dunn ES, Shi C, Caro JJ, Mahoney EM, Gabriel S, Jackson JD, Topol EJ, Cohen DJ. Chen J, et al. Value Health. 2009 Sep;12(6):872-9. doi: 10.1111/j.1524-4733.2009.00529.x. Epub 2009 Mar 11. Value Health. 2009. PMID: 19490556 Free article.
OBJECTIVE: To determine the incremental cost-effectiveness of clopidogrel plus aspirin (C + A) compared with aspirin (A) alone during the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial from a U …
OBJECTIVE: To determine the incremental cost-effectiveness of clopidogrel plus aspirin (C + A) compared with aspirin (A …
Asplatin enhances drug efficacy by altering the cellular response.
Cheng Q, Shi H, Wang H, Wang J, Liu Y. Cheng Q, et al. Metallomics. 2016 Jul 13;8(7):672-8. doi: 10.1039/c6mt00066e. Metallomics. 2016. PMID: 27125788
Asplatin, a Pt(iv) prodrug of cisplatin with the ligation of aspirin (c,c,t-[PtCl2(NH3)2(OH)(aspirin)]), demonstrates significantly higher cytotoxicity than cisplatin towards tumor cells and almost fully overcomes the drug resistance of cisplatin resis …
Asplatin, a Pt(iv) prodrug of cisplatin with the ligation of aspirin (c,c,t-[PtCl2(NH3)2(OH)(aspirin)]), demonst …
Anti-inflammatory effect of a curcumin-aspirin derivative on Ureaplasma-induced cytokine expressions in neonatal monocytes.
Jiang Y, Heqin L, Xiangping Y, Hui Y. Jiang Y, et al. Cell Mol Biol (Noisy-le-grand). 2018 Nov 30;64(14):61-65. Cell Mol Biol (Noisy-le-grand). 2018. PMID: 30511622
However, there are no available and effective remedies for suppression of the early inflammation. In this study, the effect of a curcumin-aspirin (C-A) derivative on the expressions of interleukin (IL)-10, IL-8, tumor necrosis factor (TNF)-alpha, IL-1beta, toll-like …
However, there are no available and effective remedies for suppression of the early inflammation. In this study, the effect of a curcumin- …
The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial.
Lamy A, Tong W, Gao P, Chrolavicius S, Gafni A, Yusuf S, Connolly SJ. Lamy A, et al. Can J Cardiol. 2012 Jan-Feb;28(1):95-101. doi: 10.1016/j.cjca.2011.08.112. Epub 2011 Oct 8. Can J Cardiol. 2012. PMID: 21983111 Clinical Trial.
This analysis examined cost implications of adding clopidogrel to aspirin (C+A) for ACTIVE-A patients. METHODS: Health care use was extracted for each patient. ...Stroke prevention resulted in important cost savings that offset the cost of clopidogrel. Total costs p …
This analysis examined cost implications of adding clopidogrel to aspirin (C+A) for ACTIVE-A patients. METHODS: Health care us …
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.
Serebruany VL, Malinin AI, Ziai W, Pokov AN, Bhatt DL, Alberts MJ, Hanley DF. Serebruany VL, et al. Stroke. 2005 Oct;36(10):2289-92. doi: 10.1161/01.STR.0000181081.09262.e1. Epub 2005 Sep 8. Stroke. 2005. PMID: 16151033 Clinical Trial.
BACKGROUND AND PURPOSE: Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study. To determine whether clopidogrel with aspirin
BACKGROUND AND PURPOSE: Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antipl …
Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay JF, Steinhubl SR, O'connor CM. Serebruany VL, et al. Am Heart J. 2003 Oct;146(4):713-20. doi: 10.1016/S0002-8703(03)00260-6. Am Heart J. 2003. PMID: 14564328 Clinical Trial.
Although clopidogrel is widely used in patients with acute coronary syndromes and ischemic stroke, the ability of this novel ADP-receptor antagonist to inhibit platelet function in patients with CHF is unknown. We assessed antiplatelet properties of clopidogrel with aspirin
Although clopidogrel is widely used in patients with acute coronary syndromes and ischemic stroke, the ability of this novel ADP-receptor an …
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Yoon Y, Shim WH, Lee DH, Pyun WB, Kim IJ, Jang Y, Cho SY. Yoon Y, et al. Am J Cardiol. 1999 Dec 15;84(12):1375-80. doi: 10.1016/s0002-9149(99)00579-2. Am J Cardiol. 1999. PMID: 10606107 Clinical Trial.
A combination of ticlopidine and aspirin has been accepted as the standard antithrombotic regimen after coronary stenting. ...Cilostazol, a cyclic adenosine monophosphate phosphodiesterase inhibitor, is a novel antiplatelet agent with vasodilatory properties. We compared t …
A combination of ticlopidine and aspirin has been accepted as the standard antithrombotic regimen after coronary stenting. ...Cilosta …
14 results